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A B S T R A C T   
The aim was to evaluate relevant biophysic processes related to the physicochemical features and gene trans-
fection mechanism when sphingolipids are incorporated into a cationic niosome formulation for non-viral gene 
delivery to central nervous system. For that, two formulations named niosphingosomes and niosomes devoid of 
sphingolipid extracts, as control, were developed by the oil-in water emulsion technique. Both formulations and 
the corresponding complexes, obtained upon the addition of the reporter EGFP plasmid, were physicochemically 
and biologically characterized and evaluated. Compared to niosomes, niosphingosomes, and the corresponding 
complexes decreased particle size and increased superficial charge. Although there were not significant differ-
ences in the cellular uptake, cell viability and transfection efficiency increased when human retinal pigment 
epithelial (ARPE-19) cells were exposed to niosphingoplexes. Endocytosis via caveolae decreased in the case of 
niosphingoplexes, which showed higher co-localization with lysosomal compartment, and endosomal escape 
properties. Moreover, niosphingoplexes transfected not only primary central nervous system cells, but also 
different cells in mouse retina, depending on the administration route, and brain cortex. These preliminary re-
sults suggest that niosphingosomes represent a promising non-viral vector formulation purposed for the treat-
ment of both retinal and brain diseases by gene therapy approach.   
1. Introduction 
Gene therapy is an arising medical option for treating inherited and 
acquired diseases, which has captured the interest and investment of 
many pharmaceutical companies during the last few years [1]. Its main 
concept lays on the delivery of foreign genetic material into target cell in 
order to correct a specific pathology [2]. However, the regular practice 
of this advanced technology needs to surpass many biological extracel-
lular barriers in order to reach the target cells, which depends on both 
the organ/cell type to be treated and the route of administration [3]. 
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This fact is mostly relevant in the case of immune-privileged organs, 
which are isolated from the rest of the organism by the blood–brain- 
barrier (BBB) and the blood-retinal-barrier (BRB), such as brain and 
retina, respectively [4,5]. Moreover, to be biologically effective, it is 
necessary to deliver enough genetic material inside target cells. In this 
sense, the endocytosis mechanism and the following intracellular traf-
ficking process clearly affects the final disposition of the genetic material 
at the place of action [6]. Therefore, in order to overcome both extra-
cellular and intracellular barriers, safe and effective gene delivery sys-
tems need to be developed [7]. 
Research on the design, development and application of non-viral 
vectors has considerably increased during the last years to enhance 
gene delivery efficiency [8]. Among the different kinds of non-viral 
vectors, those related to cationic lipids are the most studied ones [9]. 
In fact, Pfizer/BioNTech and Moderna companies, with the approval of 
regulatory agencies, have recently applied this lipid based-technology to 
formulate mRNA vaccines to face the devastating Covid-19 disease. Any 
slight variation in the composition of these lipid structures can impact 
on both the physicochemical properties and the gene delivery capacity 
[10]. In order to increase the biophysical activity, such cationic lipids 
are normally incorporated into colloidal vesicles made up of phospho-
lipids, leading to the formation of the corresponding liposomes [11]. If 
cationic lipids are combined with non-ionic surfactant components to 
enhance chemical stability, a colloidal dispersion of niosomes is ob-
tained [12]. Such niosomes have been recognized during last years to 
deliver efficiently and safely the genetic material for different applica-
tions [13]. In addition to cationic lipid and the non-ionic surfactant, 
other chemical agents referred as “helper” compounds can also be 
incorporated into the niosome vesicles to enhance their biological per-
formance [14]. Some compounds that have been successfully incorpo-
rated into niosomes as “helper” components include cholesterol [15], 
squalene[16], lycopene [17] or chloroquine [18], to name just a few. 
Sphingolipids are biomaterials referred as a class of natural complex 
lipids mainly found in membranes of the central nervous system tissue, 
which play a relevant biological role in cell signaling processes [19]. 
Such sphingolipids derive from sphingosine, an alkalonamime of 18 
carbons. Sphingolipids are obtained when a long saturated or unsatu-
rated fatty acid chain is bound to the amino reactive group and another 
radical consisting of phosphocholine or sugar, binds to the final carbox-
ylic group of the sphingosine, resulting in the formation of ceramides 
[20]. Sphingolipid extracts can be obtained from animals, plants, and 
can also be produced from genetically modified microorganisms. How-
ever, in mammals, endogenous sphingolipids contain high levels of 
sphingosine, which is not present in extracts from plants or in sphin-
golipids obtained from microorganisms. Therefore, sphingolipid ex-
tracts obtained from animal origin show a more suitable lipid profile to 
obtain ceramides [21]. It has been suggested that glycosphingolipids 
might be involved in the transmembrane transport and binding of bac-
teria and bacterial toxins to intestinal epithelial cells. Besides, the 
composition of glycolipids in the rat small intestinal mucosa demon-
strated alterations during normal differentiation and development, 
pointing to possible roles for glycosphingolipids in these processes as 
well [22]. 
Sphingolipids have been successfully incorporated as structural 
components into different nanocarrier systems for drug delivery pur-
poses [23–25]. However, currently, there is not any report related to the 
use of such sphingolipids on the transfection process mediated by 
cationic niosomes. Therefore, to address such issue, we performed a 
comparative study of two non-viral vector formulations based on 
cationic niosomes consisting of the same cationic lipid and non-ionic 
tensioactive, but with or without sphingolipids as “helper” compound, 
obtaining niosphingosomes or niosomes, respectively. Both formula-
tions were developed by the oil-in water (o/w) emulsion technique, and 
the corresponding complexes obtained after the addition of the EGFP 
reporter plasmid at different cationic lipid/DNA ratios (w/w) were 
physicochemically characterized before performing transfection 
experiments in ARPE-19 cells to evaluate cell viability, gene expression, 
cellular uptake and intracellular trafficking. Preliminary in vivo experi-
ments were carried out to evaluate gene expression of the most prom-
ising complexes in rat brain, after cerebral cortex injection, and in rat 
retina, after both intravitreal and subretinal administration. 
2. Materials and methods 
2.1. Preparation of formulations 
The cationic formulations were developed by the o/w emulsion 
technique. The 1, 2-di-O-octadecenyl-3-trimethylammonium propane 
chloride salt (DOTMA, Avanti Polar Lipids, Inc., Alabama, USA) cationic 
lipid, in combination with 2-2-3, 4-bis2-hydroxyethoxy oxolan-2-yl-2-2- 
hydroxyethoxy ethoxy ethyl dodecanoate (Tween 20, Bio-Rad, Madrid, 
Spain) non-ionic surfactant, were mixed or not with sphingolipids from 
animal origin found in the intestinal mucosa of mammal, which had a 
63% percentage of sphingomyelin content (Bioiberica laboratory, Sus 
scrofa, pig), as helper components, obtaining niosphingosomes and 
niosomes, respectively (Fig. 1). Briefly, the cationic lipid (3.4 mg) was 
gently grounded with sphingolipids (100 μg), then, dichloromethane 
(DCM) (500 μL) (Panreac, Barcelona, Spain) was added to this lipid 
mixture and emulsified with the non-ionic surfactant aqueous solution 
of polysorbate 20 (2.5 mL) (0.5%, w/v). Components were sonicated 
(Branson Sonifier 250, Danbury) for 30 s at 50 W. Next, the DCM organic 
solvent was evaporated and eliminated from the emulsion by using 
magnetic stirrer for 2 h at room temperature inside a extraction hood. 
Upon DCM evaporation, a colloidal dispersion containing the formula-
tions was obtained with a final cationic lipid concentration of 1.5 mg 
mL− 1. 
2.2. Plasmid propagation and complexes elaboration 
The pCMS-EGFP plasmid (Plasmid Factory, Bielefeld, Germany) was 
propagated with Escherichia coli DH5-α and purified as previously 
described [15]. The stock solution of plasmid pCMS-EGFP (0.5 mg 
mL− 1) was estimated to be around 0.137 µM (pCMS-EGFP, 5541 bp, 
average MW 3657060 g mol− 1). 
Complexes were formed by adding an appropriate volume of the 
plasmid to either niosomes or niosphingosomes at different cationic 
lipid/DNA mass ratios (w/w). The mixture was incubated for 30 min at 
room temperature before use to promote the electrostatic interactions 
between the amine groups of the cationic lipid and the phosphate groups 
of the genetic material to obtain the resulting complexes. 
2.3. Physicochemical characterization of formulations 
The hydrodynamic diameter of nanoparticles was recorded to report 
the particle size by dynamic light scattering, and laser doppler veloc-
imetry was used to determine zeta potential, using Zetasizer Nano ZS 
(Malvern Instrument, UK) as previously described [15]. All measure-
ments were performed in triplicate. Transmission electron microscopy 
(TEM) was used to define the morphology of formulations, as previously 
described [12]. 
2.4. Qualitative analysis of the transfection efficiency and cellular uptake 
To evaluate the transfection efficiency qualitatively, ARPE-19 cells 
were seeded into 24 well plates at an initial density of 18 × 104 cells per 
well, to reach 70–80% of confluence at the time of transfection assay. 
Next, cells were exposed to formulations containing EGFP (1.25 μg) 
plasmid per well during 4 h in OptiMEM® transfection medium 
(Gibco®, Life Technologies, S.A., Madrid, Spain). Afterwards, Opti-
MEM® was replaced by DMEM/F-12 regular growth medium (Gibco®, 
Life Technologies, S.A., Madrid, Spain) containing 10% bovine serum, 
and cells were allowed to grow for 48 h until their observation under 
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fluorescence microscopy. Images showing EGFP signal in ARPE-19 cells 
transfected with niosphingoplexes and nioplexes were captured at this 
time. To evaluate cellular uptake, cells were processed, fixed and 
analyzed as previously described [26]. 
2.5. Quantitative analysis of EGFP expression, cell viability and cellular 
uptake 
FACSCalibur flow cytometer (Becton Dickinson Bioscience, San Jose, 
USA) was used to perform flow cytometry analysis in order to quantify 
the percentage of EGFP and FITC-labeled EGFP plasmid (Dare Biosci-
ence) expression for transfection and cellular uptake assays, respec-
tively. For this purpose, at the end of incubation time, which was 48 h 
for transfection assay and both 2 h and 4 h for cellular uptake assay, cells 
were washed with PBS (Gibco™, San Diego, California, USA) and de-
tached from the 24 wells with trypsin/EDTA (200 μL) (Gibco™, San 
Diego, California, USA). Then, cells were prepared and analyzed as 
previously described [15]. 
2.6. Endocytic trafficking 
Cells were seeded in 24 well plates with coverslips at an initial 
density of 18 × 104 cells per well and incubated at 37 ◦C with 5% CO2 
atmosphere to reach 70–80% of confluence at the time of internalization 
assay. Next, cells were exposed to formulations containing EGFP 
plasmid (1.25 μg per well) during 3 h in OptiMEM® transfection me-
dium and endocytic fluorescent markers for 1 h at 37 ◦C and 5% CO2 
atmosphere. Briefly Transferrin Alexa Fluor 568 (2.5 μL) (5 mg mL− 1) 
was incubated to label clathrin mediated endocytosis (CME). Dextran 
Alexa Fluor 568 (30 μL) (1 mg mL− 1) a fluid-phase uptake marker, was 
used to label macropinocytosis. Cholera toxin B Alexa Fluor 594 (2.5 μL) 
(10 mg mL− 1) to label caveolae mediated endocytosis (CvME), and 
Lysotracker® (50 μL) (20 µM) to label lysosomes. All endocytic markers 
were purchased from Life Technologies (Eugene, OR, USA). Next, the 
medium containing the complexes and the endocytic markers was 
removed, and cells were washed twice with PBS. Afterwards, the cells 
were fixed, mounted and observed under fluorescence microscopy as 
described above. ImageJ software was used to quantify the co- 
localization of the green and red signal by a cross-correlation analysis 
as previously described [27]. 
2.7. Endosomal escape 
As an analogue of the endosomal compartment, anionic micelles 
based on phosphatidylserine (PS) were prepared, as described previ-
ously [28]. PS was dissolved in chloroform at 1.6 mM and left under 
magnetic stirring until the solvent was completely evaporated. Then, 
PBS was added to the dried sample and a dispersed solution was ob-
tained by sonication during 30 s at 50 w (Branson Sonifier 250, Dan-
bury). PS micelles and the complexes were incubated at a w/w ratio of 
1:50 (pCMS-EGFP: PS) for 1 h. Finally, the amount of the released DNA 
from each complex was determined by agarose gel electrophoresis after 
staining with GelRed. 
2.8. Animal model 
Embrionary E17.5 embryos from n = 4 Sprague Dawley rats were 
employed to obtain primary central nervous system cells, from the 
retinal tissue and brain cortex. Adult female C57BL/6 mice were used as 
experimental animals for subretinal, intravitreal and brain administra-
tion. All the experimental procedures were carried out in accordance 
with the RD 53/2013 Spanish and 2010/63/EU European Union regu-
lations for the use of animals in scientific research. Procedures were 
approved and supervised by the Miguel Hernandez University Standing 
Committee for Animal Use in the Laboratory with code UMH.IB. 
EFJ.03.19/02.18. 
2.9. Transfection efficiency assays of niosphingoplexes in rat primary 
retinal and neuronal cell cultures 
The chemical dissociation of the retina tissue and brain cortex, 
seeding of the cells, maintenance and transfection procedures were 
carried out as previously described [26,29] employing niosphingo-
plexes. Lipofectamine™ 2000 (Invitrogen, California, USA) at 2/1 ratio 
Fig. 1. Scheme of composition of niosphingosomes and niosomes. (a) General chemical structure of cationic lipid, non-ionic surfactant and helper component. (b) 
General scheme showing the disposition of the components in the formulations of both niosphingosomes and niosomes. 
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(w/w) was used as a positive control. Each condition was performed in 
triplicate. 
2.10. Subretinal, intravitreal and brain administration 
Adult C57BL/6 female mice (6–7 weeks old and 20–25 g body 
weight) were used as experimental animal model. Niosphingoplexes 
were injected in the eyes intravitreally (n = 3) or subretinally (n = 3) 
under an operating microscope (Zeiss OPMI® pico; Carl Zeiss Meditec 
GmbH, Jena, Germany) with the aid of a Hamilton microsyringe 
(Hamilton Co., Reno, NV), as previously described [18]. Brain admin-
istration of niosphingoplexes at cortex level were also performed in 
C57BL/6 mice (n = 3) following the procedure previously reported [29]. 
2.11. Evaluation of EGFP expression in mouse retina and brain 
EGFP expression in mouse retina was evaluated qualitatively 1 week 
after the injection of niosphingoplexes in wholemount and sagital sec-
tions of the retina, as previously described [30]. Nuclei were stained 
with Hoechst 33,342 (Thermo Fisher Scientific, Madrid, Spain) in frozen 
sections and wholemount retinas. EGFP expression in mice brains was 
evaluated qualitatively 1 week after surgery once the brain samples 
were processed, as previously described [31]. Then, the 20 µm brain 
slices were processed for immunohistochemistry. For blocking non- 
specific staining, sections were incubate in 10% BSA with 0.5% Triton 
in PBS for 1 h and then incubated overnight with chicken anti-GFP 
(Invitrogen, 1:100) diluted in PBS containing 0.5% Triton X-100. 
Then, sections were washed and incubated with Alexa Fluor 488-conju-
gated goat anti-chicken IgG (Invitrogen, 1:100) for one hour. Nuclei 
were stained with Hoechst 33342. 
2.12. Statistical analysis 
To analyze the differences between more than two groups, a 1-way 
ANOVA followed by Student–Newman–Keuls test was performed once 
normality had been proven; otherwise, the non-parametric Krus-
kal–Wallis test followed by a Mann– Whitney U test was used. Data were 
expressed as mean ± SD. A P value ≤ 0.05 was considered statistically 
significant. Analyses were performed with the IBM SPSS Statistics 22.Ink 
statistical package. 
3. Results 
3.1. Physicochemical characterization of formulations 
The physicochemical properties of the niosphingosome and niosome 
formulations, as well as the corresponding complexes obtained upon the 
addition of plasmid DNA at cationic lipid/DNA mass ratios 3/1, 7.5/1 
and 15/1, are represented in Fig. 2. The mean diameter size of nios-
phingosomes was 123.5 ± 12.5. Interestingly, this value decreased 
slightly up to 27% after the addition of plasmid DNA at all the cationic 
lipid/DNA mass ratios studied (Fig. 2a, black bars). In the case of nio-
somes, the mean diameter size before the addition of plasmid DNA was 
higher, 158.9 ± 4.4, nm and this value slightly increased to 40% at 
cationic lipid/DNA mass ratio 7.5/1, with no relevant changes at ratios 
3/1 and 15/1 (Fig. 2a, white bars). Regarding zeta potential, all for-
mulations showed positive values above zero, being zeta potential 
values of formulations containing sphingolipids higher than their 
counterparts. Before the addition of plasmid DNA, zeta potential of 
niosphingosomes and niosomes was 37.0 ± 7.8 mV and 25.0 ± 9.0 mV, 
respectively. In both cases, after the addition of plasmid DNA at cationic 
lipid/DNA mass ratio 3/1, these values declined considerably and then 
showed a moderate upward trend when incrementing the cationic lipid/ 
DNA mass ratios to 7.5/1 and 15/1 (Fig. 2a, lines). The dispersity values 
of all samples were below 0.5 (Fig. 2b) and no relevant differences were 
found between both formulations, except for niosphingoplexes at 
cationic lipid/DNA mass ratio 3/1, which presented clearly lower PDI 
values (0.19 ± 0.01) than the rest of formulations. Under TEM micro-
scopy, both sphingoniosome and niosome formulations showed a clear 
spherical and regular shape (Fig. 2c). 
3.2. Cell viability and transfection efficiency in ARPE-19 cells 
Cell viability and transfection assays were performed with nios-
phingoplexes and nioplexes at cationic lipid/DNA mass ratios 3/1, 7.5/1 
and 15/1 in ARPE-19 cells (Fig. 3) LipofectamineTM 2000 was employed 
as a positive control at 2/1 mass ratio, obtaining 39.56 ± 1.7% of live 
EGFP expressing cells. All data were normalized in relation to this value. 
As shown in Fig. 3a, niosphingoplexes at cationic lipid/DNA mass ratio 
3/1 obtained the highest transfection value (P < 0.001), with a 
normalized percentage of live EGFP expressing cells of 36.7 ± 1.6% 
(Fig. 3a, black bars). Regarding nioplexes, transfection percentages at 
cationic lipid/DNA mass ratio 3/1 were clearly lower than those values 
obtained with niosphingoplexes, around 3%, and increased to 22% and 
Fig. 2. Physicochemical characterization of formulations and complexes prepared with helper component (niosphingosomes/niosphingoplexes) and without helper 
component (niosomes/nioplexes). (a) Size (bars) and zeta potential (dots). (b) Dispersity index and standard deviation values of formulations and complexes. Each 
value represents the mean ± standard deviation of three measurements. (c) TEM images of niosphingosomes and niosomes. Scale bars: 100 nm. 
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to 15% when using cationic lipid/DNA mass ratios 7.5/1 and 15/1, 
respectively (Fig. 3a, white bars). A similar pattern was observed when 
the expression of the EGFP plasmid was analyzed by mean fluorescence 
intensity (MFI) (Fig. 3b), corroborating the highest transfection effi-
ciency of niosphingoplexes at 3/1 cationic lipid/DNA mass ratio (P <
0.05). Percentages of living cells were also higher when cells were 
exposed to niosphingoplexes, obtaining values above 80% at all condi-
tions. In the case of nioplexes, the percentage of living cells reached the 
lowest value (56%) at 7.5/1 cationic lipid/DNA mass ratio (Fig. 3a, 
lines). These data were further confirmed by fluorescence microscopy, 
where Fig. 3c shows representative images of EGFP signal in ARPE-19 
cells transfected with niosphingoplexes and with nioplexes at cationic 
lipid/DNA mass ratio 3/1. 
3.3. Cellular uptake and intracellular trafficking pathways of complexes 
in ARPE-19 cells 
Cell uptake percentages results (Figs. 4 and 6) showed that both 
nioplexes and niosphingoplexes at cationic lipid/DNA mass ratio 3/1 
were almost totally internalized by all the cells (more than 98%) at 2 h 
and 4 h of exposition. LipofectamineTM 2000 was employed as a positive 
control at 2/1 mass ratio, obtaining values around 95%. For additional 
uptake data, we also analyzed the mean fluorescence intensity (MFI) of 
the cells that internalized the complexes (Fig. 4a, dots and lines). In this 
case, again, niosphingoplexes and nioplexes showed similar values. 
However, MFI values were clearly higher for both complexes at 4 h than 
at 2 h after the exposition to niosphingoplexes (P < 0.001) or to nio-
plexes (P < 0.01). All data were normalized in relation to values ob-
tained with LipofectamineTM 2000 positive control at 2/1 mass ratio 
(95%). 
Intracellular distribution studies of these formulations in ARPE-19 
cells were qualitatively analyzed by representative confocal fluores-
cence microscopy images, showing co-localization between the intra-
cellular trafficking pathways and the complexes (Fig. 5a). The 
quantitative analysis elicited that niosphingoplexes had a less partici-
pation of the CvME pathway with a 0.25 peak value of cross-correlation 
function (CCF) compared to both CME (0.31 CCF peak value) and 
macropinocytosis (P < 0.05; 0.42 CCF peak value), as can be observed in 
Fig. 5c, (black bars). However, in the case of niosome formulations, the 
three pathways studied exhibited a more uniform participation in 
Fig. 3. Transfection efficiency and cell viability in ARPE-19 cell line 48 h post-transfection with niosphingoplexes and nioplexes. (a) Normalized percentages of 
transfection efficiency (bars) and cell viability (dots). (b) MFI of niosphingoplexes and nioplexes. Each value represents the mean ± standard deviation of three 
measurements. (c) Overlay phase contrast images showing EGFP signals in ARPE-19 cells transfected with niosphingoplexes and nioplexes at 3/1 cationic lipid/DNA 
ratio (w/w). Scale bar: 200 μm. ***P < 0.001; * P < 0.05. 
Fig. 4. Cellular uptake in ARPE-19 cell line of both niosphingoplexes and nioplexes complexes at 3/1 cationic lipid/DNA ratio (w/w). (a) Percentages of FITC-pEGFP 
positive cells (bars) and mean fluorescence intensity (dots) at 2 h and 4 h of exposition. Each value represents the mean ± standard deviation of three measurements. 
(b) Confocal microscopy images showing the cellular uptake of complexes in ARPE-19 cells at 4 h. Cell nuclei were colored in blue (DAPI); F-actin in red (Phalloidin). 
Scale bar: 50 μm. *** P < 0.001 for niosphingoplexes; ## P < 0.01 for nioplexes. 
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endocytosis process. CCF peak value was 0.35 for CME, 0.38 for mac-
ropynocytosis, and 0.41 for CvME (Fig. 5c, white bars). Additionally, the 
co-localization of the complexes with lysosomes was also evaluated. In 
this case, niosphingoplexes exhibited a higher and statistically signifi-
cant (P < 0.05) co-localization value (0.45 ± 0.03 CCF peak value) 
compared to niosomes (0.23 ± 0.05 CCF peak value). A representative 
fluoresce image obtained by confocal microscopy of the co-localization 
between complexes and lysosomes is shown in Fig. 5b. Interestingly, the 
co-incubation of the complexes with the PS micelles, that resemble the 
late endosome compartment, in an agarose gel assay showed that DNA 
incorporated in niosphingosomes was more efficiently released from the 
micelles (Fig. 5d, lane 2) than DNA bound to niosomes (Fig. 5d, lane 3). 
3.4. In vivo transfection efficiency of niosphingoplexes in mice retina and 
brain 
In vivo preliminary studies were carried out to evaluate the capacity 
of niosphingoplexes to deliver the EGFP into the mice retinas after both 
subretinal (Fig. 6a) and intravitreal (Fig. 6 b) injections. Data revealed 
that EGFP expression was present in several retinal layers including 
outer segments of photoreceptors, outer plexiform layer, inner plexiform 
layer and ganglion cell layer where some end-foot of the Müller glia cells 
(red colour) co-localized with EGFP after subretinal and intravitreal 
administration of niosphingoplexes. Additionally, EGFP expression was 
also present in the cytoplasmic extensions of cortical cells of the mice 
brains in the superficial region of the cerebral cortex injected area 
(Fig. 6c). 
4. Discussion 
Sphingolipids are amphiphilic biomolecules, with a polar terminal 
group (OH) and a hydrocarbon chain. When amphiphilic molecules are 
dispersed in water, they can spontaneously organize themselves into 
colloidal vesicles [32], which can enhance the drug delivery capacity of 
such system. Besides, sphingolipids have desirable physicochemical 
properties that can stabilize the emulsions, since their surface-active 
wetting capacity can coat the surface of crystals to enhance the hydro-
phility of hydrophobic drugs [33]. In addition to all of the above- 
mentioned properties, sphingosine, and sphingosine-1-phosphate 
among other sphingolipids metabolites, attack attention as bioactive 
signaling molecules engaged in the regulation of cell metabolism pro-
cesses, such as cell growth, differentiation, senescence, and apoptosis 
[34], by modifying the properties of cell membranes [35]. Such sphin-
gosine can be found in the sphingolipids extract obtained from animal 
origin, which show a more suitable profile to obtain ceramides [21]. 
In this study, we incorporated sphingolipids from animal origin as 
“helper” component into niosome formulations, in order to evaluate the 
biophysical properties as gene delivery system. The physicochemical 
characterization results (Fig. 2) showed that all formulations showed 
positive charge values, which is required to prevent the formation of 
aggregates due to the electrostatic interactions [16]. Moreover, all for-
mulations and complexes presented particle sizes in the nanoscale range, 
suitable for gene delivery purposes [36]. The incorporation of sphin-
golipids as “helper” component into the cationic niosome formulation 
decreased particle size. Interestingly, such differences in particle size 
were not only maintained but also decreased when the formulations 
were complexed with the EGFP plasmid. Additionally, compared to 
niosphingosomes, niosphingoplexes had a smaller particle size at all 
cationic lipid/DNA mass ratios studied, probably by due to the addi-
tional electrostatic interactions between the cationic niosphigosomes 
and the anionic plasmid DNA [15,36]. In fact, regarding superficial 
charge, the presence of sphingolipid amphiphilic biomolecules in the 
composition of niosomes increased zeta potential, and this higher zeta 
potential was maintained also at all the cationic lipid/DNA mass ratios 
Fig. 5. Intracellular trafficking pathway assay of complexes in ARPE-19 cells. (a) Confocal microscopy merged images showing ARPE-19 cells co-incubated with 
complexes containing the FITC-labeled pEGFP plasmid (green) and with one of the following endocytic vesicle markers (red): Transferrin Alexa Fluor 568 for CME, 
Dextran Alexa Fluor 568 for marcopinocytosis, and Cholera toxin B Alexa Fluor 594 for CvME. Scale bar: 50 μm. (b) Confocal microscopy merged images showing 
ARPE-19 cells co-incubated with complexes containing the FITC-labeled pEGFP plasmid (green) and with Lysotracker Red-DND-99 (red) to satin the late endosome. 
(c) Co-localization values of red and green signals assessed by cross-correlation function (CCF) analysis in complexes. Data represent the mean ± standard deviation 
of three measurements; *P < 0.05 for niosphingoplexes vs nioplexes. (d) DNA release profiles in agarose gel electrophoresis assay. Lane 1 naked DNA, lane 2 
niosphingoplexes co-incubated with PS, lane 3 nioplexes co-incubated with PS. lane 4 niosphingoplexes, lane 5 nioplexes. PS refers to phosphatidyl serine micelles. 
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studied. Regarding the dispersity index, niosphingoplexes at cationic 
lipid/DNA mass ratio 3/1 showed the lowest value of this parameter 
(0.19 ± 0.01), which point out that at this condition a better homoge-
neity of complexes is obtained. Additionally, niosphingosomes pre-
sented a clear spherical and homogeneous morphology under TEM 
examination, without aggregations, probably due to the electrostatic 
repulsion among highly positive charged particles. 
Once the formulations were characterized in physicochemical terms 
we performed in vitro gene delivery studies with niosphingoplexes and 
nioplexes at cationic lipid/DNA mass ratios 3/1, 7.5/1 and 15/1 in 
ARPE-19 cell line, since these cells play an important role in retinal 
diseases [15]. Moreover, ARPE-19 cell is a well recognized retinal cell 
model to evaluate gene transfection efficiency. Interestingly, although 
niosphingoplexes with different cationic lipid/DNA ratios showed 
similar size and zeta potential values in previously conducted physico-
chemical studies, they reported statistical differences in terms of trans-
fection efficiency and cell viability, which reveals the complexity of the 
transfection process. In particular, we observed that niosphingoplexes at 
cationic lipid/DNA mass ratio 3/1 reached the highest percentage of 
transfected cells (P < 0.001) compared to the rest of conditions. In 
parallel, MFI analysis was also analyzed to evaluate not only the per-
centage of live cells transfected, but also the intensity of the fluorescence 
signal, which is close related to the quantity of protein expressed after 
the transfection process. Such MFI studies also revealed that the highest 
intensity value was reached when ARPE-19 cells were treated with 
niosphingoplexes at 3/1 cationic lipid/DNA mass ratio. All in all, data 
obtained from transfection efficiency experiments suggest that at 3/1 
cationic lipid/DNA mass ratio, the presence of sphingolipid bio-
molecules in the niosome composition not only increases the percentage 
of transfected cells, but also the quantity of protein expressed in such 
transfected cells [15], which can have critical clinical relevance. Inter-
estingly, data obtained from the transfection experiments also revealed 
that niosphingoplexes at all cationic lipid/DNA mass ratios had higher 
cell viability values (above 80% in ARPE-19 cells), than their niosome 
counterparts, which points out the biocompatibility effect that the 
incorporation of sphingolipids has into the niosome formulation. This 
biocompatibility of niosphingoplexes was also confirmed, qualitatively, 
by the healthy appearance of ARPE-19 cells under fluorescence micro-
scope examination 48 h after transfection. By contrast, the transfection 
positive control Lipofectamine™ 2000 showed low cell viability values, 
below 65% (data not shown), revealing the toxicity associated to such 
commercial formulation, which hampers its clinical application [27]. In 
terms of clinical applications, it is also important to highlight that the 
best transfection efficiency with high cell viability was obtained when 
ARPE-19 cells were exposed to niosphingoplexes at the lowest cationic 
lipid/DNA ratio of 3/1. Such achievement would allow a higher gene 
Fig. 6. In vivo immunohistochemistry gene expression of EGFP (green) in frozen sections one week after subretinal (a), intravitreal (b) and cerebral cortex (c) in-
jections of niosphingoplexes at 3/1 cationic lipid/DNA ratio (w/w). Scale bar: 20 μm. OS, outer segments; ONL outer nuclear layer; OPL outer plexiform layer; INL 
inner nuclear layer; IPL inner plexiform layer; GCL ganglion cell layer. 
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loading capacity in small injection volumes that normally are required 
to face devastating pathologies of both brain and retina, by means of gene 
therapy approach. 
To further evaluate the impact that the incorporation of sphingolipid 
biomolecules has on the transfection process we performed also a 
cellular uptake study, since this parameter can drastically affect to the 
transfection efficiency [15]. However, our cellular uptake studies 
revealed that there were no difference in the cellular uptake of both 
formulations, in terms of both percentage of cells that internalized the 
complexes and quantity of particles that were internalized in cells. In 
any case, the internalization process was more efficient when cells were 
exposed to formulations during 4 h instead of 2 h. These data suggest the 
relevance that the kinetic of the internalization process has on the 
transfection efficiency, although in this case, there were no differences 
observed between niosphingoplexes and niosome formulations. There-
fore, we also studied other biological parameters such as the intracel-
lular trafficking process of both formulations to further explore the 
influence that the integration of sphingolipids in niosome composition 
has on the transfection process [37]. 
Intracellular trafficking studies were carried out to analyse the co- 
localization of the formulations with the most employed endocytosis 
pathways present in ARPE-19 cells such as CvME, CME and macro-
pinocitosis [38,39]. Our data revealed that the highest difference be-
tween both formulations was found in the CvME pathway. This 
endocytic pathway was minority in the case of niosphingoplexes 
formulation, which in fact preferred the macropinocitosis pathway, 
while niosomes were equally internalized by the three endocytosis 
pathways studied. Therefore, our data suggest that the presence of 
sphingolipids might turn the internalization mechanism of niosphingo-
plexes from CvME to macropinocytosis endocytic pathway. In this sense, 
it has been described that macropinocytosis is implicated in the inter-
nalization of cell penetrating peptides and proteins into cells [40,41]. 
Moreover, co-localization studies in the late endosomal compartment 
were also conducted. It this case, niosphingoplexes co-localized with 
lysosomes in a higher rate than nioplexes (Fig. 5c). It has been suggested 
that there is a suppression of lysosomal activity when complexes enter 
into ARPE-19 cells by CvME, and that such complexes are located 
around the nucleus, which hampers the release of DNA from the com-
plexes [39]. This suggestion supports our results, since compared to 
niosphingoplexes, nioplexes (that showed less transfection efficiency) 
entered into the cell mainly via CvME, with the consequent lack of 
lysosomal activity. Another critical parameter that clearly impact on 
transfection process of complexes designed for gene delivery is the 
endosomal escape. Some nucleic acid delivery systems failed to achieve 
good levels of transfection efficiencies, despite being efficiently inter-
nalized into the cells, due to their poor of endosomal escape perfor-
mance [42]. Thus, we next elaborated anionic micelles based on PS to 
evaluate the release of the complexed plasmid DNA from the late 
endosomes and avoid lysosomal degradation. As observed in Fig. 5d, a 
small amount of plasmid was released from niosphingoplexes (lane 2), 
and no release of plasmid was observed from the nioplexes (lane 3) in 
the agarose gel electrophoresis assay. Such data suggest that the incor-
poration of sphingolipids into the cationic niosome formulation could 
provide endosomal escape properties to the complexes, which in fact 
could contribute to increase transfection efficiency. Another biological 
barrier that hampers transfection process is the nuclear membrane. In 
this sense, and taking into account the crucial signaling and regulatory 
roles that sphingolipids have in the nucleus [43], it is likely that such 
sphingolipids could be promoting gene delivery by a regulatory mech-
anism in the cell nucleus. Recent findings concerning nuclear sphingo-
lipids found that different kind of sphingolipids have particular nuclear 
functions by temporally and spatially specific mechanisms. For example, 
sphingomyelin is involved in the structure and regulation of chromatin 
architecture, DNA synthesis and RNA stability, while sphingosine acts as 
ligand for the nuclear receptor steroidogenic factor 1 regulating gene 
transcription; and sphingosine-1-phosphate regulates gene expression 
epigenetically by histone acetylation [44]. 
Before perming in vivo experiments, we made a proof of concept 
assay to evaluate if niosphingoplexes at cationic lipid/DNA mass ratio 3/ 
1 (w/w) were able to deliver the EGFP plasmid in an efficient way to 
both rat embryonal retinal and cerebral cortex primary cells. Our results 
(Supplementary material) revealed EGFP expression in both retinal 
(Fig. S1a) and cortical (Fig. S1c) primary cells evaluated 72 h after 
transfection. 
Therefore, motivated by those results, niosphingoplexes were 
implemented in in vivo studies to assess their capacity to deliver the 
genetic material to mouse retina, after both intravitreal and subretinal 
injection, and to mouse brain, after administration of niosphingoplexes 
at the cortex level. Because of their relevant physiological function, both 
brain and eye are immune-privileged sites isolated from the rest of the 
organism by additional extracellular barriers such the BBB and the BRB 
[45,46]. An ideal scenario would contemplate the delivery of genetic 
material by a safe and efficient non-viral vector to immune-privileged 
sites through non-invasive administration routes, such as the topical 
instillation in the cornea that circumvent the BRB to reach the retina, 
and the nose-to-brain administration to access directly into the brain 
bypassing the BBB [47]. However, at present, this possibility is far away 
to be applied into the regular medical practice to face by gene therapy 
devastating diseases that affect the brain and retina. Therefore, we 
evaluated the local administration of niosphingoplexes in retina and 
brain. In the case of the eye, the most employed administration routes to 
reach the retina at a clinical level include the intravitreal and subretinal 
injection [18]. Our data revealed that after intravitreal and subretinal 
injections, EGFP expression was present in several layers and cells of the 
retina. More specifically, EGFP expression was observed mainly in the 
outer segments of photoreceptors, outer plexiform layer, and in the 
inner plexiform layer, where some end-foot of the Müller glia cells 
exhibited green fluorescence signal. Gene delivery to the outer layers of 
the retina is of outmost importance from a therapeutic standpoint, since 
there have been described more than 200 gene mutations at this level, 
related to relevant pathologies of the retina such us Stargardt disease, 
retinitis pigmentosa, or Leberś congenital amaurosis, to name just the 
most relevant ones [17]. On the other hand, transfection of ganglion cell 
layer in the retina has relevance to face glaucoma disease where these 
cells are affected [48]. Interestingly, in the case of brain administration 
at the cortex level, we also found EGFP expression in the cytoplasmic 
extensions of cortical cells, close to the injection site. This area of the 
brain is usually affected in devastating diseases of the central nervous 
systems, such as epilepsy, Alzheimer’s and Parkinsońs diseases, leading 
to relevant perturbation and neurological disorders [49,50]. Therefore, 
our preliminary proof of concept in vivo assay shows promising results to 
deliver in the future therapeutic genetic material into the retina and 
brain of animal models that resembles human diseases of these relevant 
and immune-privileged tissues. 
5. Conclusions 
Overall, this manuscript points out the biophysic properties of 
sphingolipid extracts from animal origin for gene delivery purposes 
when they are incorporated into cationic niosomes. Such biomaterial 
impacts not only on relevant physicochemical properties of cationic 
niosomes that influence on transfection efficiency, such as particle size 
or zeta potential, but also in biological properties, such as their intra-
cellular disposition or endosomal escape properties. Moreover, our proof 
of concept in vivo results suggest that niosphingosomes represent a 
promising non-viral vector biomaterial for the treatment of both retinal 
and brain diseases by gene therapy approach. 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
N. AL Qtaish et al.                                                                                                                                                                                                                             
European Journal of Pharmaceutics and Biopharmaceutics 169 (2021) 103–112
111
the work reported in this paper. 
Acknowledgements 
This work was supported by the Basque Country Government 
(Department of Education, University and Research, Consolidated 
Groups IT907-16). Additional funding was provided by the CIBER of 
Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), an 
initiative of the Carlos III Health Institute (ISCIII). I.V.B. and M.S.R. 
thank the University of the Basque Country (UPV/EHU) for the granted 
postdoctoral fellowship (ESPDOC19/47) and the granted pre-doctoral 
fellowship (PIF17/79), respectively. Authors wish to thank the intel-
lectual and technical assistance from the ICTS “NANBIOSIS,” more 
specifically by the Drug Formulation Unit (U10) of the CIBER in 
Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) at the 
University of Basque Country (UPV/EHU). Technical and human sup-
port provided by SGIKER (UPV/EHU) is also gratefully acknowledged. 
Appendix A. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.ejpb.2021.09.011. 
References 
[1] C.E. Dunbar, K.A. High, J.K. Joung, D.B. Kohn, K. Ozawa, M. Sadelain, Gene 
Therapy Comes of Age, Science 359 (6372) (2018), eaan4672, https://doi.org/ 
10.1126/science:aan4672. 
[2] A. Mullard, Gene Therapy Boom Continues, Nat. Rev. Drug Discov. 18 (2019), 
737–019-00154-0. 
[3] Y.K. Sung, S.W. Kim, Recent Advances in the Development of Gene Delivery 
Systems, Biomater. Res. 23 (2019), 8–019-0156-z eCollection 2019. 
[4] S. Ingusci, G. Verlengia, M. Soukupova, S. Zucchini, M. Simonato, Gene Therapy 
Tools for Brain Diseases, Front. Pharmacol. 10 (2019) 724. 
[5] J.W. Streilein, Ocular Immune Privilege: Therapeutic Opportunities from an 
Experiment of Nature, Nat. Rev. Immunol. 3 (2003) 879–889. 
[6] E.E. Vaughan, J.V. DeGiulio, D.A. Dean, Intracellular Trafficking of Plasmids for 
Gene Therapy: Mechanisms of Cytoplasmic Movement and Nuclear Import, Curr. 
Gene Ther. 6 (2006) 671–681. 
[7] N. Nayerossadat, T. Maedeh, P.A. Ali, Viral and Nonviral Delivery Systems for Gene 
Delivery, Adv. Biomed. Res. 1 (2012), 9175.98152. Epub 2012 Jul 6. 
[8] M. Foldvari, D.W. Chen, N. Nafissi, D. Calderon, L. Narsineni, A. Rafiee, Non-Viral 
Gene Therapy: Gains and Challenges of Non-Invasive Administration Methods, 
J. Control. Release 240 (2016) 165–190. 
[9] D. Zhi, Y. Bai, J. Yang, S. Cui, Y. Zhao, H. Chen, S. Zhang, A Review on Cationic 
Lipids with Different Linkers for Gene Delivery, Adv. Colloid Interface Sci. 253 
(2018) 117–140. 
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G. Martínez-Navarrete, L. Humphreys, T. López-Méndez, G. Puras, E. Fernández, J. 
L. Pedraz, Brain Angiogenesis Induced by Nonviral Gene Therapy with Potential 
Therapeutic Benefits for Central Nervous System Diseases, Mol. Pharm. 17 (6) 
(2020) 1848–1858. 
[30] I. Gallego, I. Villate-Beitia, G. Martínez-Navarrete, M. Menéndez, T. López-Méndez, 
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